

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 - 16 (Canceled).

17. (Currently amended) A method of treating ~~a condition resulting in~~ bone loss, which comprises administering an IL-1 inhibitor, a TNF- α inhibitor, and an OPG protein, wherein "OPG protein" refers to ~~an antibody to OPG ligand or~~ a polypeptide comprising conserved residues from residues 22 to 185 of SEQ ID NOS: 121, 123, and 125.
18. (Original). The method of Claim 17, wherein the TNF- α inhibitor comprises sTNFR-I, sTNFR-II, sTNFR fragments, or sTNFR-Fc, wherein "sTNFR" refers to sTNFR-I or sTNFR-II.
19. (Currently amended) The method of Claim 17, wherein the TNF- α [[\square]] inhibitor comprises sTNFR-I, sTNFR-II, sTNFR fragments, or sTNFR-Fc, wherein "sTNFR" refers to sTNFR-I or sTNFR-II.
20. (Currently amended). The method of claim 17, wherein the TNF- α [[TNF $\bar{\alpha}$]] inhibitor comprises 30 kD PEG-sTNFR-I.
21. (Previously presented). The method of claim 18, wherein the sTNFR fragment is a 2.6 kD sTNFR-I fragment.
22. (Previously presented). The method of claim 21, wherein the sTNFR-I fragment comprises 30 kD PEG.
23. (Original). The method of claim 17, wherein the TNF α inhibitor comprises sTNFR-II linked to an Fc region.

24. (Currently amended). The method of claim 17, wherein the TNF- α [[TNF α]] inhibitor is etanercept.

25. (Original). The method of Claim 17, wherein the OPG protein is OPG-Fc.

Claim 26-38 (Canceled).

39. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from ~~condition treated~~ is rheumatoid arthritis.

40. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from ~~condition treated~~ is multiple sclerosis.

41. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from ~~condition treated~~ is osteoporosis.

42. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from ~~condition treated~~ is osteomyelitis.

Claim 43 - 61 (Canceled).

62. (Previously presented) The method of Claim 17, wherein the OPG protein comprises a sequence comprising the conserved residues from residues 22 to 185 of SEQ ID NOS: 171, 172, and 173.

63. (Previously presented) The method of Claim 17, wherein the OPG protein comprises residues 22 to 185 of SEQ ID NO: 123.

64. (Previously presented) The method of Claim 17, wherein the OPG protein comprises residues 22 to 185 of SEQ ID NO: 125.

Appl. No. 09/613,591
Amdt. dated September 10, 2004
Reply to Office Action of June 10, 2004

65. (Canceled).

66. (Canceled).